Latest news
First quarter 2018 report and presentation
Oslo (Norway), 8 May 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim first quarter 2018 result. Please find enclosed the Q1 2018 report and presentation. The dose-escalation part of the fimaCHEM Phase I study in bile duct cancer continues to deliver encouraging survival data, with the latest update […]
Invitation to first quarter 2018 presentation
Oslo,Norway, 2 May 2018 – PCI Biotech invites to a presentation of the company’s first quarter 2018 report on Tuesday 8 May 2018 at Oslo Cancer Cluster Innovation Park. Time: Tuesday May 8, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. […]
PCI Biotech Holding ASA will be transferred to Oslo Børs from 27.04.2018
Oslo (Norway), 27 April 2018 – Reference is made to announcement 25.04.2018. PCI Biotech Holding ASA will be transferred from Oslo Axess to Oslo Børs from and including 27.04.2018. The shares in PCI Biotech Holding ASA will be listed with the following parameters: New – Segment: OBMA New – MIC code: XOSL Unchanged – Instrument […]